(2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid


CAS No. : 128253-31-6

(2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid,128253-31-6
Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:M117956
Synonyms:(S)-2-cyclopentyl-2-(4-(quinolin-2-ylmethoxy)phenyl)acetic acid
Molecular Formula:C23H23NO3
Molecular Weight:361.441
Target:5-Lipoxygenase
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.

refresh
Appearance:Solid powder
Purity: > 98%
Cat No:M117956
Cas No:128253-31-6
Product-Name:(2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid
IUPAC Name:(2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid
InChI:InChI=1S/C23H23NO3/c25-23(26)22(17-6-1-2-7-17)18-10-13-20(14-11-18)27-15-19-12-9-16-5-3-4-8-21(16)24-19/h3-5,8-14,17,22H,1-2,6-7,15H2,(H,25,26)/t22-/m1/s1
InChIKey:ZEYYDOLCHFETHQ-JOCHJYFZSA-N
SMILES:C1CCC(C1)C(C2=CC=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)C(=O)O
BAY-X1005 is a 5-lipoxygenase activating protein (FLAP) inhibitor. BAY-X1005 inhibits the synthesis of leukotrienes B4 and C4 in animal models and it inhibits synthesis of leukotriene B4 in A23187-stimulated leukocytes (IC50 values are 0.026, 0.039 and 0.22 μM for rat, mice and human leukocytes respectively).

1: Roger P, Gascard JP, Bara J, de Montpreville VT, Brink C. MUC5AC mucin release from human airways in vitro: effects of indomethacin and Bay X1005. Mediators Inflamm. 2001 Feb;10(1):33-6. PubMed PMID: 11324902; PubMed Central PMCID: PMC1781691.
2: Nagai H, Takeda H, Uno T, Tanaka H, Matsuo A. Effect of a novel leukotoriene synthesis inhibitor, BAY x1005, on the antigen-and LPS-induced airway hyperresponsiveness in guinea pigs. Prostaglandins. 1996 Feb;51(2):139-48. PubMed PMID: 8711135.
3: Rossoni G, Sala A, Berti F, Testa T, Buccellati C, Molta C, Muller-Peddinghaus R, Maclouf J, Folco GC. Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes. J Pharmacol Exp Ther. 1996 Jan;276(1):335-41. PubMed PMID: 8558451.
4: Hatzelmann A, Goossens J, Fruchtmann R, Mohrs KH, Raddatz S, Müller-Peddinghaus R. Inversely-correlated inhibition of human 5-lipoxygenase activity by BAY X1005 and other quinoline derivatives in intact cells and a cell-free system--implications for the function of 5-lipoxygenase activating protein. Biochem Pharmacol. 1994 Jun 15;47(12):2259-68. PubMed PMID: 8031320.
5: Gardiner PJ, Cuthbert NJ, Francis HP, Fitzgerald MF, Thompson AM, Carpenter TG, Patel UP, Newton BB, Mohrs K, Müller-Peddinghaus R, et al. Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAY x1005. Eur J Pharmacol. 1994 Jun 2;258(1-2):95-102. PubMed PMID: 7925604.
6: Gorenne I, Labat C, Gascard JP, Norel X, Müller-Peddinghaus R, Mohrs KH, Taylor WA, Gardiner PJ, Brink C. (R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl] acetic acid (BAY x1005), a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human airways. J Pharmacol Exp Ther. 1994 Feb;268(2):868-72. PubMed PMID: 8114000.
7: Hatzelmann A, Fruchtmann R, Mohrs KH, Raddatz S, Matzke M, Pleiss U, Keldenich J, Müller-Peddinghaus R. Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X1005. Implications for biological regulation of 5-lipoxygenase. Adv Prostaglandin Thromboxane Leukot Res. 1994;22:23-31. Review. PubMed PMID: 7771337.
8: Müller-Peddinghaus R, Kohlsdorfer C, Theisen-Popp P, Fruchtmann R, Perzborn E, Beckermann B, Bühner K, Ahr HJ, Mohrs KH. BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. J Pharmacol Exp Ther. 1993 Oct;267(1):51-7. PubMed PMID: 8229782.
9: Müller-Peddinghaus R, Fruchtmann R, Ahr HJ, Beckermann B, Bühner K, Fugmann B, Junge B, Matzke M, Kohlsdorfer C, Raddatz S, et al. BAY X1005, a new selective inhibitor of leukotriene synthesis: pharmacology and pharmacokinetics. J Lipid Mediat. 1993 Mar-Apr;6(1-3):245-8. PubMed PMID: 8395246.
10: Fruchtmann R, Mohrs KH, Hatzelmann A, Raddatz S, Fugmann B, Junge B, Horstmann H, Müller-Peddinghaus R. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions. 1993 Mar;38(3-4):188-95. PubMed PMID: 8213345.

Related Products
  • CAS No. :5968-70-7
    Product Name:

    β-acetyl-Boswellic Acid

    Cat No: I010636 View details
  • CAS No. :118569-21-4
    Product Name:

    Zileuton sodium

    Cat No: I000661 View details
  • CAS No. :1532593-30-8
    Product Name:

    ML355

    Cat No: I001921 View details
  • CAS No. :118414-82-7
    Product Name:

    MK-886

    Cat No: I000650 View details